Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Capital Medical University |
---|---|
Information provided by: | Capital Medical University |
ClinicalTrials.gov Identifier: | NCT00538044 |
we try to use simvastatin in the treatment of advanced pulmoary hypertension secondary to congenital heart disease or chronic pulmonary embolism before and after the operation.
Condition | Intervention | Phase |
---|---|---|
Hypertension, Pulmonary |
Drug: simvastatin |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind (Investigator), Placebo Control, Parallel Assignment |
Official Title: | the Clinical Research Using Simvastatin as a Medication to Treat Advanced Secondary Pulmonary Hypertension |
Study Start Date: | January 2009 |
Estimated Study Completion Date: | January 2012 |
Arms | Assigned Interventions |
---|---|
1simvastatin group: Experimental
before the operation, the patient start the simvastatin medication on the dosage of 40mg per day
|
Drug: simvastatin
medication with simvastation on the dosage of 40mg per day before the operation and all the time after the operation
|
2contral group: No Intervention
just do routin operation with no use of simvastatin, other medication is exact the same as the simvastatin group
|
advanced pulmonary hypertension is refractory to the medication in use nowaday, especially pulmonary hypertension secondary to congenital heart disease or chronic pulmonary embolism.It is revealed that statins may intefere the pathogenisis of the pulmonary hypertension in many key poing, such as improving apotosis or inhiting the proliferation of pulmonary vascular smooth muscle cell. so we try to use simvastatin in the treatment of advanced pulmoary hypertension secondary to congenital heart disease or chronic pulmonary embolism before and after the operation.
Ages Eligible for Study: | 12 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Huili Gan, MD,Ph.D. | 13001277863 | ganhuili@hotmail.com |
China | |
Beijing Anzhen Hospital | |
Beijing, China, 100029 |
Study Chair: | Huili Gan, MD,Ph.D. | Beijing Anzehn Hospital |
Study ID Numbers: | Gan1, Anzhen1 |
Study First Received: | October 1, 2007 |
Last Updated: | October 1, 2007 |
ClinicalTrials.gov Identifier: | NCT00538044 |
Health Authority: | China: Ethics Committee |
pulmonary hypertension simvastatin advanced pulmonary hypertension secondary to congenital heart disease advanced pulmonary hypertension secondary to chronic pulmonary embolism |
Heart Diseases Pulmonary Embolism Respiratory Tract Diseases Simvastatin Embolism Hypertension, Pulmonary |
Lung Diseases Vascular Diseases Neoplasm Metastasis Secondary pulmonary hypertension Hypertension |
Antimetabolites Molecular Mechanisms of Pharmacological Action Therapeutic Uses Antilipemic Agents Enzyme Inhibitors |
Cardiovascular Diseases Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions |